24 November 2015 - AbbVie today announced that Health Canada granted a Notice of Compliance to Technivie (ombitasvir/paritaprevir/ritonavir tablets) in combination with ribavirin for the treatment of adults with genotype 4 chronic hepatitis C virus infection without cirrhosis who are either treatment naïve or previously treated with peginterferon and ribavirin.

For more details, go to: http://www.newswire.ca/news-releases/abbvies-technivie-receives-health-canada-approval-for-genotype-4-chronic-hepatitis-c-infection-553141181.html